Phase 1 trial of a novel C’Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα).
Wen Wee(Roswell Park Comprehensive Cancer Center), Eliel Bayever(Knite (United States)), Carey K. Anders(Duke University), Catherine W. Reddick(Knite (United States)), Yonina R. Murciano‐Goroff(Memorial Sloan Kettering Cancer Center), Gregory P. Adams(University of Colorado Denver), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Cesar A. Perez(Sarah Cannon), Erika Hamilton(Sarah Cannon), Yujie Zhao(Shandong University of Traditional Chinese Medicine), Douglas Orr(Mary Crowley Cancer Research Center)
Cited by 7
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917